First-Line Treatment of Hairy Cell Leukemia with Cladribine Followed by Rituximab Consolidation Significantly Improves Leukemia-Free Survival

Clin Lymphoma Myeloma Leuk. 2021 Aug;21(8):564-566. doi: 10.1016/j.clml.2021.04.001. Epub 2021 Apr 10.

Authors

Ghid Amhaz¹, Ali Ibrahim¹, Ulfat Usta², Jean El Cheikh¹, Ali Bazarbachi¹, Iman Abou Dalle³

Affiliations

¹ Division of Hematology-Oncology, American University of Beirut Medical Center, Beirut, Lebanon.
² Department of Pharmacology, American University of Beirut Medical Center, Beirut, Lebanon.
³ Division of Hematology-Oncology, American University of Beirut Medical Center, Beirut, Lebanon. Electronic address: ia41@aub.edu.lb.

PMID: 33994319
DOI: 10.1016/j.clml.2021.04.001

No abstract available

Publication types

Editorial
Letter

MeSH terms

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Cladribine / therapeutic use*
Consolidation Chemotherapy
Disease-Free Survival
Female
Humans
Leukemia, Hairy Cell / drug therapy*
Leukemia, Hairy Cell / pathology
Male
Middle Aged
Remission Induction
Rituximab / therapeutic use*

Substances

Cladribine
Rituximab